GlaxoSmithKline, Britain's biggest drugmaker, is placing a small but important bet on a new way of treating diseases by targeting electrical signals in the body.

The company said on Wednesday it would offer a $1 million prize to stimulate innovation in the field, as well as funding up to 40 researchers working in external laboratories.


The University of Maryland (UM) BioPark announced today that the Global Virus Network (GVN) is the Park’s newest tenant. The GVN is a non-profit organization comprised of the top medical virologist in more than 30 institutions spanning 21 nations – and growing. GVN's mission is to combat emerging pandemic viral threats and current viral killers through international collaborative research, training the next generation of medical virologist, education and advocacy.   

Said Jim Hughes, President, Research Park Corporation, University of Maryland Baltimore, “It’s exciting for the UM BioPark to include the prestigious Global Virus Network as one of our tenants. We are also pleased to be able to offer GVN continued close proximity to its Scientific Director, Co-Founder, and world-renowned virus researcher Dr. Robert Gallo from the UM School of Medicine, whose Institute of Human Virology is located conveniently just down the street from the GVN’s new BioPark headquarters.” 


Pluristem Therapeutics (NASDSQ: PSTI) announced today that following favorable preclinical studies, United Therapeutics Corporation received approval to perform a human Phase I study in Australia using Pluristem's PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem's PLX-PAD cells for PAH.

PAH is characterized by abnormally high blood pressure in the arteries of the lungs and leads to an increased workload on the right side of the heart.

Sanofi piers

Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin® program. Under the existing framework of the 2010 agreement, the new program will entitle Pieris to an upfront payment from Sanofi and committed research funding as well as payments for the achievement of research, preclinical, regulatory and commercial milestones. Specific financial terms were not disclosed.


A test that detects human papillomavirus, a virus directly related to cervical cancer, has hit the market following approval by the China Food and Drug Administration.

"The careHPV test is faster, better and cheaper," says Qiao Youlin, a respected epidemiologist, who headed a research project into the development of careHPV between 2003 and 2008. The research was assisted by the Bill & Melinda Gates Foundation, which contributed $13 million to the project.


Company: MedImmune Booth/Stand: 3344 Event: 2013 BIO International ConventionApr 22 - 25 2013 Chicago IL US

About MedImmune

MedImmune is the worldwide biologics research and development arm of AstraZeneca a global innovation-driven biopharmaceutical business that focuses on the discovery development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. MedImmune has approximately 2500 employees globally with its headquarters located in Gaithersburg Md. one of AstraZeneca’s three global R&D centers. For more information please visit


When engineers at this university learned of a Baltimore neurosurgeon’s struggle to operate on sensitive parts of the brain, they designed a tiny robot to maneuver around more precisely than instruments held by a human hand during surgery — something Loh said never would have happened if the neurosurgeon and robotic engineers had not met. Now, one year into the partnership, the universities have launched a collaborative public health school, developed a joint biomedical informatics and bioimaging center and created a research and innovation program.

“When you have a formal structure for a partnership and encourage people to talk to each other, this is what the partnership between the universities is all about,” Loh said. “They have the problems; we have the solutions.”


I launched a literary magazine in college. I actually thought that was a good idea. After a few too many 16-hour days of hustling ads and desperately scrounging for content, my grades tanked and my blood pressure skyrocketed. I learned that special kind of panic that comes from trying to execute on the inflated ambitions of a 20-year-old. The process consumed everything. (For the record, I regret nothing.)

My point is: The university setting is great for being entrepreneurial. But it takes organization and drive to hold it all together — something I realized I didn't have. At least some of these young founders do.


The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, announced the finalists for its 25th Annual Dinner and Awards Celebration. Winners will be announced at the awards dinner on May 16 at the Bethesda North Marriott Hotel and Conference Center.

“This year’s finalists are a testament to the ingenuity and vibrancy of Maryland’s technology and life sciences community,” said Larry Letow, TCM’s chairman. “Their innovations advance the cause of a healthier, safer world while fostering job creation and prosperity here in Maryland. Simply put, Maryland’s tech and biotech companies are essential to our long-term economic growth. The TCM’s Awards Celebration is a great way to celebrate our members’ tremendous achievements to date and the bright future that lies ahead.”


Nominate your best startups to present to a select group of invitation-only investors and Global 1000 companies as part of the Virtual Startups Showcase (VSS) and the Exits Startups Showcase + Conference in San Francisco


  • For University Startups: Friday, April 26, 2013
  • For Accelerator, Angel Investor and VC Portfolio Companies: Friday, June 14, 2013

The National Council on Entrepreneurial Tech Transfer (NCET2) asks universities, accelerators, Angel investors and VC's to nominate their best startups and have them present to a select group of invitation-only investors and Global 1000 companies.


WIScience Scholarship: The Premier Catalyst for Developing Women Leaders in Science

Are you nearing completion of your graduate degree or fellowship, and wondering how you’re going to transition into the healthcare industry? Do you get nervous thinking about how to identify the career in healthcare that fits you best?  Do you wish you had a mentor to discuss these concerns with?  If so, then you are the perfect candidate to apply for the WIScience Scholarship: The Premier Catalyst for Developing Women Leaders in Science offered by the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association (HBA). 


The Maryland House of Delegates has passed a measure to adjust how money from a state venture capital fund can be used to try to make it more effective.

The House voted 107-25 on Saturday for the bill. That sends it to the Senate to consider amendments delegates made to the measure.

Medimmune logo

Those who join MedImmune feel a sense of ownership about their future. They thrive with a recognized leader in the biotechnology industry and the wholly-owned subsidiary of AstraZeneca plc.

Here, you will join passionate professionals who advance science, technology and medicine to develop products designed to help people live better lives. You will excel in an environment characterized by respect, integrity and growth opportunities…that encourages both individual contribution and collaborative entrepreneurial thinking. Our products and/or product candidates are designed to address areas of need in infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. Explore a MedImmune career as we strive to better more lives, more often, around the world.


GlaxoSmithKline ( GSK ) recently announced that it has initiated a phase III study to evaluate the use of Benlysta (belimumab) in patients suffering from anti-neutrophil cytoplasmic antibodies (ANCA) positive vasculitis.

The multi-centre, randomized, double-blind phase III study will assess the efficacy and safety profile of Benlysta in combination with azathioprine as a maintenance therapy in ANCA positive vasculitis patients.


There’s an interesting trend I’ve noticed with at least one healthcare accelerator I have been tracking. The members of the startups for the most part have increasingly more industry experience and seem more adept at finding pain points and delivering a workable solution to members of the healthcare ecosystem. And if the successes of Blueprint Health’s latest graduating class are anything to go by, healthcare companies are getting increasingly receptive to working with startups that can help them address some of the demands of the Affordable Care Act and some of its impacts with more innovative solutions.


Seeking to maximize ongoing research, innovative ideas and revenue-generating opportunities, more schools are creating entrepreneur-in-residence programs -- and letting the experts do the work.

With millions of dollars of research funding and teams of experts at their disposal, more universities are seeking ways to turn research breakthroughs into business opportunities.


Among 400 applications from 22 countries, 13 early stage healthcare companies have been chosen for a three-year entrepreneurship class run by StartUp Health and GE, according to a statement from the companies. The class members will each be assigned a GE mentor who matches their business model and get access to the resources the Fortune 50 company can wield to help scale their consumer health innovations. That could include working with GE Healthymagination, GE Healthcare, GE Capital, or some of its business units, depending on the members’ specific needs.


AstraZeneca 's ( AZN ) worldwide biologics research and development (R&D) unit, MedImmune recently acquired AlphaCore Pharma, a biotechnology company based in Michigan. Financial terms of the deal were not disclosed by the companies.

We note that the acquisition of AlphaCore Pharma adds ACP-501 (a recombinant human lecithin-cholesterol acyltransferase/ LCAT enzyme) to AstraZeneca's pipeline. The candidate is being developed for acute coronary syndromes (ACS) and other high-risk atherosclerosis conditions for the rapid removal of tissue cholesterol.


Digital health incubator Rock Health released data today that shows an increase in funding for med-tech startups in the first quarter of 2013.

Thirty-seven health deals were valued at a total of $365 million, which is 35 percent higher than the first quarter of 2012, “suggesting that 2013 will be another record year for the digital health industry,” the blog post reads.


A big-data revolution is under way in health care. Start with the vastly increased supply of information. Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, while payors and providers have digitized their patient records. Meanwhile, the US federal government and other public stakeholders have been opening their vast stores of health-care knowledge, including data from clinical trials and information on patients covered under public insurance programs. In parallel, recent technical advances have made it easier to collect and analyze information from multiple sources—a major benefit in health care, since data for a single patient may come from various payors, hospitals, laboratories, and physician offices.


Johns Hopkins researcher Se-Jin Lee was named Wednesday as the 2013 recipient of the Ho-Am Prize in Medicine, which recognizes outstanding accomplishments in medical research that pave the way to conquering disease. It is awarded each year to an ethnic Korean and is sometimes referred to as “Korea's Nobel.”

Lee is best known for his discovery of myostatin, a hormone that regulates muscle mass, and related work that lays the foundation for new therapies for conditions such as muscle wasting and muscular dystrophy.


Philadelphia has reached a milestone in its efforts to be recognized as a healthcare and life sciences hub with the start of its first health IT accelerator.

DreamIt Health’s inaugural class includes 10 startups. The four-month program co-sponsored by Independence Blue Cross and Penn Medicine includes members seeking to develop tools for healthcare providers to speed up diagnoses and improve outcomes.


Maryland has invested $500,000 in Cytomedix Inc., a regenerative medicine company in Gaithersburg.

The investment was made through the state's Maryland Venture Fund and InvestMaryland program. The state said the money is part of a $27.5 million fundraising round by Cytomedix (OTC: CMXI) that will result in the company adding 13 new employees to its current staff of 55.


Tom Sadowski, President and CEO, of the Economic Alliance of Greater Baltimore has been appointed to UMBC’s Public Policy External Advisory Board. Created in 2003, the External Advisory Board provides advice and guidance to UMBC’s Department of Public Policy and the Maryland Institute for Policy Analysis and Research (MIPAR). An important part of their mission is to bring the University’s public policy expertise to bear on the concerns of the communities they serve.


Gaithersburg-based MedImmune, which is gaining hundreds of jobs in a consolidation by parent company AstraZeneca PLC, has completed its acquisition of AlphaCore Pharma LLC for an undisclosed sum.

The Ann Arbor, Mich.-based biotechnology company is developing a drug for high cholesterol. Cardiovascular and metabolic disease is one of MedImmune's core research areas.


GlaxoSmithKline is trying to expand the market for its Benlysta drug beyond lupus by launching a major study of the medicine as a treatment for a serious blood vessel disorder.

GSK acquired full control of Benlysta when it bought Human Genome Sciences for $3 billion last year. Current sales of the drug are modest, at 70 million pounds ($106 million) in 2012, but GSK hopes it will become a major seller.


Since the passage of the Jumpstart Our Business Startups (JOBS) Act (H.R. 3606) last year, the financial and medical press has been buzzing about the potential for crowdfunding to revolutionize fundraising for early-stage biotech companies. Even more recently, a portal that is exclusively dedicated to crowdfunding biotech and healthcare start-ups launched at Although there may be reason for biotech entrepreneurs to be excited about crowdfunding, there are significant limitations and risks to this approach as well.

Wexford biomed

BioMed Realty Adds 1.6 Million Square Foot Portfolio & Expands University / Research Institution Segment to 18% of Annualized Base Rents

BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it has entered into a definitive agreement to merge with Wexford Science & Technology, LLC, a subsidiary of Wexford Equities, LLC, furthering BioMed Realty’s position as the leading provider of real estate to the life science industry. Wexford Science & Technology is a private real estate investment and development company that owns and develops institutional quality life science real estate for academic and medical research organizations, and that boasts well-regarded skills for urban development and redevelopment of life science real estate. The aggregate consideration for Wexford Science & Technology is approximately $640 million, excluding transaction costs and subject to adjustment based on working capital levels and construction and development costs incurred prior to closing. Wexford Science & Technology will operate as a wholly owned subsidiary of BioMed Realty.


And then there were nine.

The Maryland Department of Business and Economic Development has named three finalists in three separate categories of the final round of the InvestMaryland Challenge. The winning companies, to be announced April 15, will receive $100,000 in top prizes and $125,000 in cash and in-kind awards as part of the Maryland Venture Fund’s first business competition.

InvestMaryland is a state venture capital initiative managed by DBED and the state-run Maryland Venture Fund. The initiative raised $84 million through a tax credit auction in 2012 to invest in startup companies.


Monday, April 15th 5:30 - 8:30 p.m. at MICA's Brown Center

After months of submitting business plans, scoring applications, developing special awards and partnering with us, it’s time to celebrate entrepreneurship! Please join us April 15th at Maryland Institute College of Art’s Brown Center as we announce the top three $100K winners.